Latest Breaking News On - Publication annual report - Page 5 : comparemela.com

Hyloris Pharmaceuticals: Hyloris Reports Full Year 2020 Financial Results On track to fuel the pipeline with =4 new product candidates in 2021 Strong cash position of €64 million year-end to execute ambitious growth plan 14 commercial products expected by 2024 Conference call and Liège, Belgium - 9 March 2021 - Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to bringing innovative treatments that offer added value to underserved patient populations, today reports its consolidated financial results and a business update for the year ended 31 December 2020, recent achievements, and an outlook for 2021. Stijn Van Rompay, Chief Executive Officer of Hyloris, commented: I am extremely proud of the significant progress we have made across all areas of our business, which has set a strong foundation to execute our ambitious growth plan. We are committed to changing the lives of patients by applying our knowhow and innovative technol

United statesHong kongUnited kingdomCzech republicRegion flamandeUnited arab emiratesAbuz abyNew zealandAmber fennellVan rompayKensington pharmaBiocapital europeOlivier declercqChris welshMarc foidartMarieke vermeersch